Inhibitor kinazy Brutona u chorych z nawrotowym lub opornym na leczenie chloniakiem z komórek plaszcza - Wyniki miedzynarodowego, wieloosrodkowego, badania II fazy z ibrutynibem (PCI-32765) - EHA Encore

Translated title of the contribution: Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma - Results of an international, multicenter, phase 2 study of Ibrutinib (PCI-32765) - EHA Encore

Wojciech Jurczak, Simon Rule, Peter Martin, Rebecca Auer, Brad S. Kahl, Agnieszka Giza, Bozena Jachimczak, Ranjana H. Advani, Jorge Romaguera, Michael Williams, Jacqueline Barrientos, Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Jesse McGreivy, Fong Clow, Darrin M. Beaupre, Lori Kunkel, Andre Goy, Kristie A. BlumWiktor Jedrzejczak, Michael L. Wang

Research output: Contribution to journalArticle

Abstract

Bruton's tyrosine kinase (BTK) is a central mediator of B-cell receptor (BCR) signaling essential for normal B-cell development. Ibrutinib is an oral BTK inhibitor that induces apoptosis and inhibits migration and adhesion of malignant B-cells. Updated results of this international, multicenter, phase 2 study of single agent ibrutinib in relapsed or refractory MCL will be presented. Ibrutinib 560 mg PO QD was administered continuously until disease progression. Tumor response was assessed every 2 cycles (one cycle = 28 days). The study enrolled 115 patients (65 bortezomib-naïve, 50 bortezomib-exposed); 111 patients were treated; 110 were evaluable for response. Baseline characteristics included: median age 68 years, time since diagnosis 42 months, number of prior treatments 3; bulky disease (<10 cm) 13%, prior stem cell transplant 10%, high risk MIPI 49%. Median time on treatment was 9.2 months; 53% of patients remain on therapy. Median PFS was 13.9 months and DOR has not yet been reached. Responses increased with longer treatment: comparing to previous data described at ASH 2011, the CR rate increased from 16% to 39%, and the ORR increased from 69% to 75%.

Translated title of the contributionTargeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma - Results of an international, multicenter, phase 2 study of Ibrutinib (PCI-32765) - EHA Encore
Original languagePolish
Pages (from-to)314-318
Number of pages5
JournalActa haematologica Polonica
Volume44
Issue number3
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Keywords

  • Bruton kinase
  • Ibrutynib
  • Mantle cell lymphoma

Fingerprint Dive into the research topics of 'Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma - Results of an international, multicenter, phase 2 study of Ibrutinib (PCI-32765) - EHA Encore'. Together they form a unique fingerprint.

  • Cite this

    Jurczak, W., Rule, S., Martin, P., Auer, R., Kahl, B. S., Giza, A., Jachimczak, B., Advani, R. H., Romaguera, J., Williams, M., Barrientos, J., Chmielowska, E., Radford, J., Stilgenbauer, S., McGreivy, J., Clow, F., Beaupre, D. M., Kunkel, L., Goy, A., ... Wang, M. L. (2013). Inhibitor kinazy Brutona u chorych z nawrotowym lub opornym na leczenie chloniakiem z komórek plaszcza - Wyniki miedzynarodowego, wieloosrodkowego, badania II fazy z ibrutynibem (PCI-32765) - EHA Encore. Acta haematologica Polonica, 44(3), 314-318. https://doi.org/10.1016/j.achaem.2013.07.013